Mikhail Eydelman - 07 Dec 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
07 Dec 2023
Net transactions value
-$369,354
Form type
4
Filing time
11 Dec 2023, 16:36:02 UTC
Previous filing
04 Oct 2023
Next filing
04 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $214,100 +10,000 +48% $21.41 31,035 07 Dec 2023 Direct F1
transaction PCVX Common Stock Sale $565,000 -10,000 -32% $56.50 21,035 07 Dec 2023 Direct F2
transaction PCVX Common Stock Tax liability $18,454 -325 -1.5% $56.78 20,710 07 Dec 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 +10,000 +5.4% $0.000000 195,000 07 Dec 2023 Common Stock 10,000 $21.41 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 548 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
F3 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F4 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.